CoChat

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

BACKGROUND: While immune checkpoint blockade has greatly improved clinical outcomes in diseases such as melanoma, there remains a need for predictive biomarkers to determine who will likely benefit most from which therapy. To date, most biomarkers of response have been identified in the tumors themselves. Biomarkers that could be assessed from peripheral blood would be even more desirable, because of ease of access and reproducibility of sampling. METHODS: We used mass cytometry (CyTOF) to comprehensively profile peripheral blood of melanoma patients, in order to find predictive biomarkers of response to anti-CTLA-4 or anti-PD-1 therapy. Using a panel of ~ 40 surface and intracellular markers, we performed in-depth phenotypic and functional immune profiling to identify potential predictive biomarker candidates. RESULTS: memory/non-memory cells and other memory subsets was different between responders and non-responders to anti-CTLA-4 therapy. In anti-PD-1 (but not anti-CTLA-4) treated patients, we discovered differences in CD69 and MIP-1β expressing NK cells between responders and non-responders. Finally, multivariate analysis was used to develop a model for the prediction of response. CONCLUSIONS: memory T cell subsets play an important role in response to anti-CTLA-4, and are potential biomarker candidates. For anti-PD-1 therapy, NK cell subsets (but not memory T cell subsets) correlated with clinical response to therapy. These functionally active NK cell subsets likely play a critical role in the anti-tumor response triggered by anti-PD-1.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-018-0328-8

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 viSNE analysis of CyTOF data results in well-defined immune subset maps in PBMC. Preliminary gating of CyTOF data to define live intact single cells, was performed in CytoBank. Then viSNE mapping of the healthy donor PBMC and patient baseline PBMC are shown. a All ungated events were sequentially gated in Cytobank to identify live intact single cell events as described in Methods. a) 191Ir DNA1 and 140Ce beads were used to identify cells. b) Singlets were identified by gating on cells positive for the DNA markers 191Ir DNA1 and 193Ir DNA2. c) Event Length of singlets from b) was used to obtain intact singlets. d) Live intact singlets were obtained by gating for intact singlets from c) which were negative for dead cell marker 115In maleimide DOTA. Subsequent viSNE analysis was performed using live intact single cell events obtained from d). b viSNE map of healthy donor PBMC showing distinct immune subsets. The heat spectrum associated with each graph indicates the relative expression level of each marker. c Various immune subsets were grouped into distinct islands on the viSNE map
Fig. 1 viSNE analysis of CyTOF data results in well-defined immune subset maps in PBMC. Preliminary gating of CyTOF data to define live intact single cells, was performed in CytoBank. Then viSNE mapping of the healthy donor PBMC and patient baseline PBMC are shown. a All ungated events were sequentially gated in Cytobank to identify live intact single cell events as described in Methods. a) 191Ir DNA1 and 140Ce beads were used to identify cells. b) Singlets were identified by gating on cells positive for the DNA markers 191Ir DNA1 and 193Ir DNA2. c) Event Length of singlets from b) was used to obtain intact singlets. d) Live intact singlets were obtained by gating for intact singlets from c) which were negative for dead cell marker 115In maleimide DOTA. Subsequent viSNE analysis was performed using live intact single cell events obtained from d). b viSNE map of healthy donor PBMC showing distinct immune subsets. The heat spectrum associated with each graph indicates the relative expression level of each marker. c Various immune subsets were grouped into distinct islands on the viSNE mapCC BY · PubMed Central
Fig. 2 Non-responders to anti-PD-1 had lower CD69 and MIP-1β expressing NK cells following PMA + Ionomycin stimulation. Pre-treatment PBMC from melanoma patients who were responders or non-responders to anti-PD-1 therapy were stimulated with PMA + Ionomycin ex vivo, and analyzed by CyTOF. Frequencies of (a) CD69+, (b) MIP-1β+ and (c) CD69+MIP-1β+ NK cells are shown. *p < 0.05
Fig. 2 Non-responders to anti-PD-1 had lower CD69 and MIP-1β expressing NK cells following PMA + Ionomycin stimulation. Pre-treatment PBMC from melanoma patients who were responders or non-responders to anti-PD-1 therapy were stimulated with PMA + Ionomycin ex vivo, and analyzed by CyTOF. Frequencies of (a) CD69+, (b) MIP-1β+ and (c) CD69+MIP-1β+ NK cells are shown. *p < 0.05CC BY · PubMed Central
Fig. 3 Melanoma patients who responded to anti-CTLA-4 therapy had higher frequencies of memory T cells in baseline PBMC. CyTOF data from baseline PBMC of melanoma patients treated with anti-CTLA-4. Frequencies of (a) CD45RA+ cells in CD4+ and CD8+ T cell compartments; (b) CD45RA− cells in CD4+ and CD8+ T cell compartments. c-f Memory subsets of CD4+ and CD8+ T cells in responders versus non-responders. c Frequencies of naïve (CD45RA+CCR7+) and Central Memory (Tcm, CD45RA−CCR7+) CD4+ T cells. d Frequencies of Effector Memory (Tem, CD45RA−CCR7−) and Terminal Effector (Teff, CD45RA+CCR7−) CD4+ T cells. c Frequencies of naïve (CD45RA+CCR7+) and Central Memory (Tcm, CD45RA−CCR7+) CD8+ T cells. d Frequencies of Effector Memory (Tem, CD45RA−CCR7−) and Terminal Effector (Teff, CD45RA+CCR7−) CD8+ T cells. *p < 0.05; **p < 0.01
Fig. 3 Melanoma patients who responded to anti-CTLA-4 therapy had higher frequencies of memory T cells in baseline PBMC. CyTOF data from baseline PBMC of melanoma patients treated with anti-CTLA-4. Frequencies of (a) CD45RA+ cells in CD4+ and CD8+ T cell compartments; (b) CD45RA− cells in CD4+ and CD8+ T cell compartments. c-f Memory subsets of CD4+ and CD8+ T cells in responders versus non-responders. c Frequencies of naïve (CD45RA+CCR7+) and Central Memory (Tcm, CD45RA−CCR7+) CD4+ T cells. d Frequencies of Effector Memory (Tem, CD45RA−CCR7−) and Terminal Effector (Teff, CD45RA+CCR7−) CD4+ T cells. c Frequencies of naïve (CD45RA+CCR7+) and Central Memory (Tcm, CD45RA−CCR7+) CD8+ T cells. d Frequencies of Effector Memory (Tem, CD45RA−CCR7−) and Terminal Effector (Teff, CD45RA+CCR7−) CD8+ T cells. *p < 0.05; **p < 0.01CC BY · PubMed Central
Fig. 4 Multivariate predictive models for response to anti-CTLA-4 treatment. Multivariate analysis based on the FlowJo gating of CyTOF data was performed to generate a model that predicts clinical response to anti-CTLA-4 monotherapy. The heatmap is row-normalized and shows the four features used by the model with the highest area under the curve (AUC). Each value in the heatmap corresponds to a cell population as determined by manual gating, where red indicates a larger population and blue a smaller one. The signature coefficients (grey bars) on the left side indicate the elastic net weights, which corresponds to the importance in the prediction model. The clinical response of each patient is indicated in green (responder) and red (non-responder) as a horizontal bar above the heat map. The predictions of clinical response for each patient are indicated in grey (responders) and black (non-responders), where the height of the vertical bar represents the probability output of the predictor. The receiver operating characteristic (ROC) curve for the model is shown on the right
Fig. 4 Multivariate predictive models for response to anti-CTLA-4 treatment. Multivariate analysis based on the FlowJo gating of CyTOF data was performed to generate a model that predicts clinical response to anti-CTLA-4 monotherapy. The heatmap is row-normalized and shows the four features used by the model with the highest area under the curve (AUC). Each value in the heatmap corresponds to a cell population as determined by manual gating, where red indicates a larger population and blue a smaller one. The signature coefficients (grey bars) on the left side indicate the elastic net weights, which corresponds to the importance in the prediction model. The clinical response of each patient is indicated in green (responder) and red (non-responder) as a horizontal bar above the heat map. The predictions of clinical response for each patient are indicated in grey (responders) and black (non-responders), where the height of the vertical bar represents the probability output of the predictor. The receiver operating characteristic (ROC) curve for the model is shown on the rightCC BY · PubMed Central
Fig. 5 Parameters that correlate with anti-CTLA-4 and anti-PD-1 clinical response were verified by the automated Citrus algorithm. CyTOF .fcs files were analyzed using the Citrus algorithm to establish a predictive model for anti-CTLA-4 treatment. (a) Citrus clustering of immune subsets (represented by metal_marker channels) based on CyTOF data from baseline PBMCs of anti-CTLA-4 treated patients are shown as graphs. The distribution of each immune subset is presented as an individual graph. The heat spectrum associated with each graph indicates the expression level of each channel in a cluster. (b) A Nearest Shrunken Centroid (PAMR) model described the minimum number of channels and clusters needed to distinguish responders from non-responders to anti-CTLA-4 with the lowest error rate. (c) Comparisons of metal signal intensities (mean) of indicated channels are shown from left to right: CD45RA (153Eu) in base CD4+ and CD8+ clusters, and PD-L2 (172Yb) intensity in the base monocyte cluster in responders vs. non-responders to anti-CTLA-4 therapy. Two clusters from the Citrus predictive model in (b) are not demonstrated in (c) The cluster highlighted for the signal of HLA-DR (157Gd) is not associated with any major immune subsets in this analysis. The cluster highlighted for the signal of CD38 (156Gd) is the base cluster of total PBMC§. §CD38 expression on total PBMC was also assessed, and no significant difference between responders and non-responders was found in the univariate analysis.
Fig. 5 Parameters that correlate with anti-CTLA-4 and anti-PD-1 clinical response were verified by the automated Citrus algorithm. CyTOF .fcs files were analyzed using the Citrus algorithm to establish a predictive model for anti-CTLA-4 treatment. (a) Citrus clustering of immune subsets (represented by metal_marker channels) based on CyTOF data from baseline PBMCs of anti-CTLA-4 treated patients are shown as graphs. The distribution of each immune subset is presented as an individual graph. The heat spectrum associated with each graph indicates the expression level of each channel in a cluster. (b) A Nearest Shrunken Centroid (PAMR) model described the minimum number of channels and clusters needed to distinguish responders from non-responders to anti-CTLA-4 with the lowest error rate. (c) Comparisons of metal signal intensities (mean) of indicated channels are shown from left to right: CD45RA (153Eu) in base CD4+ and CD8+ clusters, and PD-L2 (172Yb) intensity in the base monocyte cluster in responders vs. non-responders to anti-CTLA-4 therapy. Two clusters from the Citrus predictive model in (b) are not demonstrated in (c) The cluster highlighted for the signal of HLA-DR (157Gd) is not associated with any major immune subsets in this analysis. The cluster highlighted for the signal of CD38 (156Gd) is the base cluster of total PBMC§. §CD38 expression on total PBMC was also assessed, and no significant difference between responders and non-responders was found in the univariate analysis.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 1

  1. Hastie T, Tibshirani R, Narasimham B, Chu G. Pam: prediction analysis for microarrays 2011.

Cited by

See all 190

Metadata

Authors
Subrahmanyam, P. B., Dong, Z., Gusenleitner, D., Giobbie-Hurder, A., Severgnini, M., Zhou, J., Manos, M., Eastman, L. M., Maecker, H. T., & Hodi, F. S.
Affiliations
  • Stanford Medicine (US)
  • Harvard University (US)
Corresponding author
Hodi, F. Stephen
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2018-03-06
Volume
6
Issue
1
Pages
18-18
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2800568511
Cited by
190
References
33
Citations by year
2026: 5 · 2025: 10 · 2024: 14 · 2023: 25 · 2022: 27 · 2021: 35 · 2020: 32 · 2019: 22 · 2018: 20
FWCI
10.22
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Cancer Institute (1R21CA205430)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
melanoma, predictive biomarkers, CTLA-4 blockade, anti-PD-1 therapy, immune checkpoint blockade, mass cytometry, T cell memory subsets, natural killer cells, CD69, MIP-1β, treatment response prediction
MeSH terms
Antineoplastic Agents, Immunological, Adult, Aged, Female, Humans, Immunotherapy, Killer Cells, Natural, Male, Melanoma, Middle Aged, Skin Neoplasms, Biomarkers, CD4-Positive T-Lymphocytes, Treatment Outcome, CD8-Positive T-Lymphocytes, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. https://app.cochat.ai/papers/10.1186/s40425-018-0328-8
The paper
Subrahmanyam, P. B., Dong, Z., Gusenleitner, D., Giobbie-Hurder, A., Severgnini, M., Zhou, J., Manos, M., Eastman, L. M., Maecker, H. T., & Hodi, F. S. (2018). Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-018-0328-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.